logo

Automated mini-invasive surgical approach to the treatment of mitral insufficiency

Sector: Hospital • Location: France

Source: EU Funding & Tenders Portal

Project
Ended

Mitral valve insufficiency is a heart condition, where blood is abnormally leaking out of the mitral valve. This condition mainly afflicts the elderly patients: - 80% of patients aged 80+ show moderate symptoms (chronic fatigue, shortness of breath, palpitations, racing heart rate) - 10% of patients above 75 with severe symptoms are at risk of a sudden death (stroke) within 5 years. - Prevalence

Project Information FAQ

Project Information

4 Q
The project “Automated mini-invasive surgical approach to the treatment of mitral insufficiency” is an infrastructure initiative in the Hospital sector, located in France. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Mitral valve insufficiency is a heart condition, where blood is abnormally leaking out of the mitral valve. This condition mainly afflicts the elderly patients: - 80% of patients aged 80+ show moderate symptoms (chronic fatigue, shortness of breath, palpitations, racing heart rate) - 10% of patients above 75 with severe symptoms are at risk of a sudden death (stroke) within 5 years. - Prevalence will double by 2030. Mitral insufficiency is treated with open heart surgery (300,000 operations/year in the EU and the USA) followed by intensive care. But this operation is unbearable for fragile patients. Half of the patients above 75 are tagged inoperable because of their age. Less invasive repair surgeries have been tested (annuloplasty by transfemoral surgery) but lack efficiency and safety and require highly skilled surgeons (not available in each hospital). In this context, the company CMI’nov has developed MITrep, the first patented mini-invasive surgical device that automatically goes to the mitral valve with no trial and error to affix a leak-preventing ring on the valve. It uses the transapical approach. Once the ring is anchored, the mitral valve returns to normal activity. No heavy post-surgery effects are expected. No intensive care required. MITrep can be used by any surgeons : no need to be a mitral valve specialist. It will allow to halve the operation time (from 5 hours to less than 2 hours), reduce hospitalization time to 3 days (vs 5-8 days with 2 days in ICU) and cost about three times less than open heart surgery (30k€ vs 80+k€). It means a dramatic cost reduction for healthcare systems and a real improvement of the care of the elderly patient. This project holds the ambition to build a new gold standard in valvuloplasty worldwide, starting with mitral repair and replicable to aortic and tricuspid valve repair. It is also a value driver for CMI’nov. The Phase 1 project will validate the feasibility of MITrep before scale-up and deployment.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data